Hetlioz FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved January 31, 2014)
Brand name: Hetlioz
Generic name: tasimelteon
Dosage form: Capsules
Company: Vanda Pharmaceuticals Inc.
Treatment for: Non-24-Hour Disorder; Smith-Magenis Syndrome Sleep Disturbance
Hetlioz (tasimelteon) is a melatonin receptor agonist for the treatment of Non-24-Hour Disorder in adults, and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.
Development Timeline for Hetlioz
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.